Mucopolysaccharidoses: Lysosomal Storage Disorders and Connective Tissue
Abnormalities
Mucopolysaccharidoses (MPS) represent a group of 11 inherited lysosomal storage disorders
arising from deficiencies in enzymes degrading glycosaminoglycans (GAGs). Substrate
accumulation disrupts connective tissues, bones, joints, cartilage, corneas, and organs. Seven
major types (I-VII) exist based upon deficiencies in specific enzymes degrading GAGs.
While variable in severity, progressive multisystem involvement causes major impairments
requiring lifelong care. Newborn screening, hematopoietic stem cell transplantation (HSCT),
and emerging enzyme replacement therapies (ERTs) benefit selected MPS populations.
Further understanding of disease pathogenesis promises novel therapies alleviating
progressive multi-organ involvement characterizing these disorders.
GAG Metabolism and Physiological Roles
Glycosaminoglycans (GAGs) crucially regulate tissue structure, cell signaling, and
development:
- Heparan sulfate, dermatan sulfate, chondroitin sulfate, keratan sulfate compose GAG
chainosities.
- Lysosomal hydrolases degrade GAG disaccharides and monomers for recycling or
excretion.
- Cell surface/extracellular matrix accumulation impacts morphogenesis, inflammatory
responses, growth factor binding when catabolized GAGs accumulate.
Deficient catabolic enzyme activities cause progressive GAG storage clinically evident across
MPS subtypes. Understanding substrate processing deficits rationalizes therapeutic targeting
strategies.
Clinical Features by Enzyme Deficiency
Dependent upon lysosomal deficiency, manifestations involve:
MPS I - IDUA
- Hurler (+/-Hurler-Scheie/Scheie variants), severe organomegaly, facial dysmorphism,
coronary artery, valve disease.
MPS II - IDS
- Hunter syndrome, primarily skeletal abnormalities, myocardial/valvular disease risk.
MPS III - SGSH
- Sanfilippo A/B/C/D, primarily neurological decline without somatic features in
childhood/adolescence.
MPS IVA - GALNS
- Morquio A, skeletal dysplasia, short stature, coronary, valve abnormalities.
MPS VI - ARSB
- Maroteaux-Lamy syndrome, skeletal, ophthalmologic, valvular abnormalities.
Multisystem involvement severity depends upon residual enzyme activities from unique
genetic etiologies across MPS subtypes.
Genetics of MPS
All are autosomal recessive except X-linked MPS II:
- Over 100 pathogenic variants degrade single enzyme activities through truncations,
missense changes impacting stability/catalytic function.
- Variable expressivity from allelic variants, somatic mosaicism impacting severity within
subtypes and between patients.
- Carrier testing assesses risks to relatives, prenatal/preimplantation diagnosis utilized by
carriers for progeny wellbeing.
Establishing causative variants confirms molecular diagnosis facilitating natural history
insights and guiding therapeutic intervention rationale.
Diagnosis
Suspicion stems from characteristic clinical/radiographic features:
- Dysmorphic facies, organomegaly, orthopedic/ocular abnormalities on examination.
- Elevated urinary GAGs by sulfated glycosaminoglycan assay initially screens.
- Enzyme activity assays on leukocytes/fibroblasts confirm specific deficiencies.
- Molecular analysis establishes causative variants in genes encoding deficient enzymes.
Baseline assessment guides establishing molecular diagnosis, prognosis estimation and
intervention planning through multidisciplinary care teams.
Management Strategies
Addressing multisystem involvement holistically:
- Palliative symptom management optimizes outcomes for neurological/non-CNS variants
ineligible for transplantation/ERT.
- Surgical corrections address visual, airway, cardiovascular abnormalities.
- Physical/occupational therapy maintains joint range of motion/mobility.
- Hematopoietic stem cell transplantation halts progression when available.
- Enzyme replacement therapy stabilizes/reverses manifestations in approved subtypes.
- Investigational intrathecal ERT explores neurological variants’ high CSF barriers.
- Preimplantation genetic diagnosis enables unaffected offspring.
Continued advances leveraging pathophysiological understanding promise further therapies
alleviating burdens from these lysosomal disorders’ progressive multi-organ involvement.
Future Directions
Progressing management through precision development:
- Clarifying genotype-phenotype correlations guides intervention timing.
- Advancing newborn screening/early diagnosis before irreversible damage occurs.
- Developing intrathecal/intraventricular ERT delivery across neurological variants.
- Gene therapies approach beyond hematopoietic cell transplantation.
- Disease modeling illuminates modifier genes impacting heterogeneity.
- Biomarkers sensitively monitor disease course under various interventions.
- Designing adjunctive small molecules targeting storage/pathology mechanisms.
Overall, interdisciplinary efforts decoding dysregulated GAG degradation promise refining
management frameworks through rational therapeutic targeting mitigating impact for
individuals living with these progressive multisystem disorders.
Mucopolysaccharidoses (MPS) represent a group of 11 inherited lysosomal storage disorders
arising from deficiencies in enzymes degrading glycosaminoglycans (GAGs). Substrate
accumulation disrupts connective tissues, bones, joints, cartilage, corneas, and organs. Seven
major types (I-VII) exist based upon deficiencies in specific enzymes degrading GAGs.
While variable in severity, progressive multisystem involvement causes major impairments
requiring lifelong care. Newborn screening, hematopoietic stem cell transplantation (HSCT),
and emerging enzyme replacement therapies (ERTs) benefit selected MPS populations.
Further understanding of disease pathogenesis promises novel therapies alleviating
progressive multi-organ involvement characterizing these disorders.
GAG Metabolism and Physiological Roles
Glycosaminoglycans (GAGs) crucially regulate tissue structure, cell signaling, and
development:
- Heparan sulfate, dermatan sulfate, chondroitin sulfate, keratan sulfate compose GAG
chainosities.
- Lysosomal hydrolases degrade GAG disaccharides and monomers for recycling or
excretion.
- Cell surface/extracellular matrix accumulation impacts morphogenesis, inflammatory
responses, growth factor binding when catabolized GAGs accumulate.
Deficient catabolic enzyme activities cause progressive GAG storage clinically evident across
MPS subtypes. Understanding substrate processing deficits rationalizes therapeutic targeting
strategies.
Clinical Features by Enzyme Deficiency
Dependent upon lysosomal deficiency, manifestations involve:
MPS I - IDUA
- Hurler (+/-Hurler-Scheie/Scheie variants), severe organomegaly, facial dysmorphism,
coronary artery, valve disease.
MPS II - IDS
- Hunter syndrome, primarily skeletal abnormalities, myocardial/valvular disease risk.
MPS III - SGSH
- Sanfilippo A/B/C/D, primarily neurological decline without somatic features in
childhood/adolescence.
MPS IVA - GALNS
- Morquio A, skeletal dysplasia, short stature, coronary, valve abnormalities.
MPS VI - ARSB
- Maroteaux-Lamy syndrome, skeletal, ophthalmologic, valvular abnormalities.
Multisystem involvement severity depends upon residual enzyme activities from unique
genetic etiologies across MPS subtypes.
Genetics of MPS
All are autosomal recessive except X-linked MPS II:
- Over 100 pathogenic variants degrade single enzyme activities through truncations,
missense changes impacting stability/catalytic function.
- Variable expressivity from allelic variants, somatic mosaicism impacting severity within
subtypes and between patients.
- Carrier testing assesses risks to relatives, prenatal/preimplantation diagnosis utilized by
carriers for progeny wellbeing.
Establishing causative variants confirms molecular diagnosis facilitating natural history
insights and guiding therapeutic intervention rationale.
Diagnosis
Suspicion stems from characteristic clinical/radiographic features:
- Dysmorphic facies, organomegaly, orthopedic/ocular abnormalities on examination.
- Elevated urinary GAGs by sulfated glycosaminoglycan assay initially screens.
- Enzyme activity assays on leukocytes/fibroblasts confirm specific deficiencies.
- Molecular analysis establishes causative variants in genes encoding deficient enzymes.
Baseline assessment guides establishing molecular diagnosis, prognosis estimation and
intervention planning through multidisciplinary care teams.
Management Strategies
Addressing multisystem involvement holistically:
- Palliative symptom management optimizes outcomes for neurological/non-CNS variants
ineligible for transplantation/ERT.
- Surgical corrections address visual, airway, cardiovascular abnormalities.
- Physical/occupational therapy maintains joint range of motion/mobility.
- Hematopoietic stem cell transplantation halts progression when available.
- Enzyme replacement therapy stabilizes/reverses manifestations in approved subtypes.
- Investigational intrathecal ERT explores neurological variants’ high CSF barriers.
- Preimplantation genetic diagnosis enables unaffected offspring.
Continued advances leveraging pathophysiological understanding promise further therapies
alleviating burdens from these lysosomal disorders’ progressive multi-organ involvement.
Future Directions
Progressing management through precision development:
- Clarifying genotype-phenotype correlations guides intervention timing.
- Advancing newborn screening/early diagnosis before irreversible damage occurs.
- Developing intrathecal/intraventricular ERT delivery across neurological variants.
- Gene therapies approach beyond hematopoietic cell transplantation.
- Disease modeling illuminates modifier genes impacting heterogeneity.
- Biomarkers sensitively monitor disease course under various interventions.
- Designing adjunctive small molecules targeting storage/pathology mechanisms.
Overall, interdisciplinary efforts decoding dysregulated GAG degradation promise refining
management frameworks through rational therapeutic targeting mitigating impact for
individuals living with these progressive multisystem disorders.
Mucopolysaccharidoses (MPS) represent a group of 11 inherited lysosomal storage disorders
arising from deficiencies in enzymes degrading glycosaminoglycans (GAGs). Substrate
accumulation disrupts connective tissues, bones, joints, cartilage, corneas, and organs. Seven
major types (I-VII) exist based upon deficiencies in specific enzymes degrading GAGs.
While variable in severity, progressive multisystem involvement causes major impairments
requiring lifelong care. Newborn screening, hematopoietic stem cell transplantation (HSCT),
and emerging enzyme replacement therapies (ERTs) benefit selected MPS populations.
Further understanding of disease pathogenesis promises novel therapies alleviating
progressive multi-organ involvement characterizing these disorders.
GAG Metabolism and Physiological Roles
Glycosaminoglycans (GAGs) crucially regulate tissue structure, cell signaling, and
development:
- Heparan sulfate, dermatan sulfate, chondroitin sulfate, keratan sulfate compose GAG
chainosities.
- Lysosomal hydrolases degrade GAG disaccharides and monomers for recycling or
excretion.
- Cell surface/extracellular matrix accumulation impacts morphogenesis, inflammatory
responses, growth factor binding when catabolized GAGs accumulate.
Deficient catabolic enzyme activities cause progressive GAG storage clinically evident across
MPS subtypes. Understanding substrate processing deficits rationalizes therapeutic targeting
strategies.
Clinical Features by Enzyme Deficiency
Dependent upon lysosomal deficiency, manifestations involve:
MPS I - IDUA
- Hurler (+/-Hurler-Scheie/Scheie variants), severe organomegaly, facial dysmorphism,
coronary artery, valve disease.
MPS II - IDS
- Hunter syndrome, primarily skeletal abnormalities, myocardial/valvular disease risk.
MPS III - SGSH
- Sanfilippo A/B/C/D, primarily neurological decline without somatic features in
childhood/adolescence.
MPS IVA - GALNS
- Morquio A, skeletal dysplasia, short stature, coronary, valve abnormalities.
MPS VI - ARSB
- Maroteaux-Lamy syndrome, skeletal, ophthalmologic, valvular abnormalities.
Multisystem involvement severity depends upon residual enzyme activities from unique
genetic etiologies across MPS subtypes.
Genetics of MPS
All are autosomal recessive except X-linked MPS II:
- Over 100 pathogenic variants degrade single enzyme activities through truncations,
missense changes impacting stability/catalytic function.
- Variable expressivity from allelic variants, somatic mosaicism impacting severity within
subtypes and between patients.
- Carrier testing assesses risks to relatives, prenatal/preimplantation diagnosis utilized by
carriers for progeny wellbeing.
Establishing causative variants confirms molecular diagnosis facilitating natural history
insights and guiding therapeutic intervention rationale.
Diagnosis
Suspicion stems from characteristic clinical/radiographic features:
- Dysmorphic facies, organomegaly, orthopedic/ocular abnormalities on examination.
- Elevated urinary GAGs by sulfated glycosaminoglycan assay initially screens.
- Enzyme activity assays on leukocytes/fibroblasts confirm specific deficiencies.
- Molecular analysis establishes causative variants in genes encoding deficient enzymes.
Baseline assessment guides establishing molecular diagnosis, prognosis estimation and
intervention planning through multidisciplinary care teams.
Management Strategies
Addressing multisystem involvement holistically:
- Palliative symptom management optimizes outcomes for neurological/non-CNS variants
ineligible for transplantation/ERT.
- Surgical corrections address visual, airway, cardiovascular abnormalities.
- Physical/occupational therapy maintains joint range of motion/mobility.
- Hematopoietic stem cell transplantation halts progression when available.
- Enzyme replacement therapy stabilizes/reverses manifestations in approved subtypes.
- Investigational intrathecal ERT explores neurological variants’ high CSF barriers.
- Preimplantation genetic diagnosis enables unaffected offspring.
Continued advances leveraging pathophysiological understanding promise further therapies
alleviating burdens from these lysosomal disorders’ progressive multi-organ involvement.
Future Directions
Progressing management through precision development:
- Clarifying genotype-phenotype correlations guides intervention timing.
- Advancing newborn screening/early diagnosis before irreversible damage occurs.
- Developing intrathecal/intraventricular ERT delivery across neurological variants.
- Gene therapies approach beyond hematopoietic cell transplantation.
- Disease modeling illuminates modifier genes impacting heterogeneity.
- Biomarkers sensitively monitor disease course under various interventions.
- Designing adjunctive small molecules targeting storage/pathology mechanisms.
Overall, interdisciplinary efforts decoding dysregulated GAG degradation promise refining
management frameworks through rational therapeutic targeting mitigating impact for
individuals living with these progressive multisystem disorders.
Mucopolysaccharidoses (MPS) represent a group of 11 inherited lysosomal storage disorders
arising from deficiencies in enzymes degrading glycosaminoglycans (GAGs). Substrate
accumulation disrupts connective tissues, bones, joints, cartilage, corneas, and organs. Seven
major types (I-VII) exist based upon deficiencies in specific enzymes degrading GAGs.
While variable in severity, progressive multisystem involvement causes major impairments
requiring lifelong care. Newborn screening, hematopoietic stem cell transplantation (HSCT),
and emerging enzyme replacement therapies (ERTs) benefit selected MPS populations.
Further understanding of disease pathogenesis promises novel therapies alleviating
progressive multi-organ involvement characterizing these disorders.
GAG Metabolism and Physiological Roles
Glycosaminoglycans (GAGs) crucially regulate tissue structure, cell signaling, and
development:
- Heparan sulfate, dermatan sulfate, chondroitin sulfate, keratan sulfate compose GAG
chainosities.
- Lysosomal hydrolases degrade GAG disaccharides and monomers for recycling or
excretion.
- Cell surface/extracellular matrix accumulation impacts morphogenesis, inflammatory
responses, growth factor binding when catabolized GAGs accumulate.
Deficient catabolic enzyme activities cause progressive GAG storage clinically evident across
MPS subtypes. Understanding substrate processing deficits rationalizes therapeutic targeting
strategies.
Clinical Features by Enzyme Deficiency
Dependent upon lysosomal deficiency, manifestations involve:
MPS I - IDUA
- Hurler (+/-Hurler-Scheie/Scheie variants), severe organomegaly, facial dysmorphism,
coronary artery, valve disease.
MPS II - IDS
- Hunter syndrome, primarily skeletal abnormalities, myocardial/valvular disease risk.
MPS III - SGSH
- Sanfilippo A/B/C/D, primarily neurological decline without somatic features in
childhood/adolescence.
MPS IVA - GALNS
- Morquio A, skeletal dysplasia, short stature, coronary, valve abnormalities.
MPS VI - ARSB
- Maroteaux-Lamy syndrome, skeletal, ophthalmologic, valvular abnormalities.
Multisystem involvement severity depends upon residual enzyme activities from unique
genetic etiologies across MPS subtypes.
Genetics of MPS
All are autosomal recessive except X-linked MPS II:
- Over 100 pathogenic variants degrade single enzyme activities through truncations,
missense changes impacting stability/catalytic function.
- Variable expressivity from allelic variants, somatic mosaicism impacting severity within
subtypes and between patients.
- Carrier testing assesses risks to relatives, prenatal/preimplantation diagnosis utilized by
carriers for progeny wellbeing.
Establishing causative variants confirms molecular diagnosis facilitating natural history
insights and guiding therapeutic intervention rationale.
Diagnosis
Suspicion stems from characteristic clinical/radiographic features:
- Dysmorphic facies, organomegaly, orthopedic/ocular abnormalities on examination.
- Elevated urinary GAGs by sulfated glycosaminoglycan assay initially screens.
- Enzyme activity assays on leukocytes/fibroblasts confirm specific deficiencies.
- Molecular analysis establishes causative variants in genes encoding deficient enzymes.
Baseline assessment guides establishing molecular diagnosis, prognosis estimation and
intervention planning through multidisciplinary care teams.
Management Strategies
Addressing multisystem involvement holistically:
- Palliative symptom management optimizes outcomes for neurological/non-CNS variants
ineligible for transplantation/ERT.
- Surgical corrections address visual, airway, cardiovascular abnormalities.
- Physical/occupational therapy maintains joint range of motion/mobility.
- Hematopoietic stem cell transplantation halts progression when available.
- Enzyme replacement therapy stabilizes/reverses manifestations in approved subtypes.
- Investigational intrathecal ERT explores neurological variants’ high CSF barriers.
- Preimplantation genetic diagnosis enables unaffected offspring.
Continued advances leveraging pathophysiological understanding promise further therapies
alleviating burdens from these lysosomal disorders’ progressive multi-organ involvement.
Future Directions
Progressing management through precision development:
- Clarifying genotype-phenotype correlations guides intervention timing.
- Advancing newborn screening/early diagnosis before irreversible damage occurs.
- Developing intrathecal/intraventricular ERT delivery across neurological variants.
- Gene therapies approach beyond hematopoietic cell transplantation.
- Disease modeling illuminates modifier genes impacting heterogeneity.
- Biomarkers sensitively monitor disease course under various interventions.
- Designing adjunctive small molecules targeting storage/pathology mechanisms.
Overall, interdisciplinary efforts decoding dysregulated GAG degradation promise refining
management frameworks through rational therapeutic targeting mitigating impact for
individuals living with these progressive multisystem disorders.
Mucopolysaccharidoses (MPS) represent a group of 11 inherited lysosomal storage disorders
arising from deficiencies in enzymes degrading glycosaminoglycans (GAGs). Substrate
accumulation disrupts connective tissues, bones, joints, cartilage, corneas, and organs. Seven
major types (I-VII) exist based upon deficiencies in specific enzymes degrading GAGs.
While variable in severity, progressive multisystem involvement causes major impairments
requiring lifelong care. Newborn screening, hematopoietic stem cell transplantation (HSCT),
and emerging enzyme replacement therapies (ERTs) benefit selected MPS populations.
Further understanding of disease pathogenesis promises novel therapies alleviating
progressive multi-organ involvement characterizing these disorders.
GAG Metabolism and Physiological Roles
Glycosaminoglycans (GAGs) crucially regulate tissue structure, cell signaling, and
development:
- Heparan sulfate, dermatan sulfate, chondroitin sulfate, keratan sulfate compose GAG
chainosities.
- Lysosomal hydrolases degrade GAG disaccharides and monomers for recycling or
excretion.
- Cell surface/extracellular matrix accumulation impacts morphogenesis, inflammatory
responses, growth factor binding when catabolized GAGs accumulate.
Deficient catabolic enzyme activities cause progressive GAG storage clinically evident across
MPS subtypes. Understanding substrate processing deficits rationalizes therapeutic targeting
strategies.
Clinical Features by Enzyme Deficiency
Dependent upon lysosomal deficiency, manifestations involve:
MPS I - IDUA
- Hurler (+/-Hurler-Scheie/Scheie variants), severe organomegaly, facial dysmorphism,
coronary artery, valve disease.
MPS II - IDS
- Hunter syndrome, primarily skeletal abnormalities, myocardial/valvular disease risk.
MPS III - SGSH
- Sanfilippo A/B/C/D, primarily neurological decline without somatic features in
childhood/adolescence.
MPS IVA - GALNS
- Morquio A, skeletal dysplasia, short stature, coronary, valve abnormalities.
MPS VI - ARSB
- Maroteaux-Lamy syndrome, skeletal, ophthalmologic, valvular abnormalities.
Multisystem involvement severity depends upon residual enzyme activities from unique
genetic etiologies across MPS subtypes.
Genetics of MPS
All are autosomal recessive except X-linked MPS II:
- Over 100 pathogenic variants degrade single enzyme activities through truncations,
missense changes impacting stability/catalytic function.
- Variable expressivity from allelic variants, somatic mosaicism impacting severity within
subtypes and between patients.
- Carrier testing assesses risks to relatives, prenatal/preimplantation diagnosis utilized by
carriers for progeny wellbeing.
Establishing causative variants confirms molecular diagnosis facilitating natural history
insights and guiding therapeutic intervention rationale.
Diagnosis
Suspicion stems from characteristic clinical/radiographic features:
- Dysmorphic facies, organomegaly, orthopedic/ocular abnormalities on examination.
- Elevated urinary GAGs by sulfated glycosaminoglycan assay initially screens.
- Enzyme activity assays on leukocytes/fibroblasts confirm specific deficiencies.
- Molecular analysis establishes causative variants in genes encoding deficient enzymes.
Baseline assessment guides establishing molecular diagnosis, prognosis estimation and
intervention planning through multidisciplinary care teams.
Management Strategies
Addressing multisystem involvement holistically:
- Palliative symptom management optimizes outcomes for neurological/non-CNS variants
ineligible for transplantation/ERT.
- Surgical corrections address visual, airway, cardiovascular abnormalities.
- Physical/occupational therapy maintains joint range of motion/mobility.
- Hematopoietic stem cell transplantation halts progression when available.
- Enzyme replacement therapy stabilizes/reverses manifestations in approved subtypes.
- Investigational intrathecal ERT explores neurological variants’ high CSF barriers.
- Preimplantation genetic diagnosis enables unaffected offspring.
Continued advances leveraging pathophysiological understanding promise further therapies
alleviating burdens from these lysosomal disorders’ progressive multi-organ involvement.
Future Directions
Progressing management through precision development:
- Clarifying genotype-phenotype correlations guides intervention timing.
- Advancing newborn screening/early diagnosis before irreversible damage occurs.
- Developing intrathecal/intraventricular ERT delivery across neurological variants.
- Gene therapies approach beyond hematopoietic cell transplantation.
- Disease modeling illuminates modifier genes impacting heterogeneity.
- Biomarkers sensitively monitor disease course under various interventions.
- Designing adjunctive small molecules targeting storage/pathology mechanisms.
Overall, interdisciplinary efforts decoding dysregulated GAG degradation promise refining
management frameworks through rational therapeutic targeting mitigating impact for
individuals living with these progressive multisystem disorders.
Mucopolysaccharidoses (MPS) represent a group of 11 inherited lysosomal storage disorders
arising from deficiencies in enzymes degrading glycosaminoglycans (GAGs). Substrate
accumulation disrupts connective tissues, bones, joints, cartilage, corneas, and organs. Seven
major types (I-VII) exist based upon deficiencies in specific enzymes degrading GAGs.
While variable in severity, progressive multisystem involvement causes major impairments
requiring lifelong care. Newborn screening, hematopoietic stem cell transplantation (HSCT),
and emerging enzyme replacement therapies (ERTs) benefit selected MPS populations.
Further understanding of disease pathogenesis promises novel therapies alleviating
progressive multi-organ involvement characterizing these disorders.
GAG Metabolism and Physiological Roles
Glycosaminoglycans (GAGs) crucially regulate tissue structure, cell signaling, and
development:
- Heparan sulfate, dermatan sulfate, chondroitin sulfate, keratan sulfate compose GAG
chainosities.
- Lysosomal hydrolases degrade GAG disaccharides and monomers for recycling or
excretion.
- Cell surface/extracellular matrix accumulation impacts morphogenesis, inflammatory
responses, growth factor binding when catabolized GAGs accumulate.
Deficient catabolic enzyme activities cause progressive GAG storage clinically evident across
MPS subtypes. Understanding substrate processing deficits rationalizes therapeutic targeting
strategies.
Clinical Features by Enzyme Deficiency
Dependent upon lysosomal deficiency, manifestations involve:
MPS I - IDUA
- Hurler (+/-Hurler-Scheie/Scheie variants), severe organomegaly, facial dysmorphism,
coronary artery, valve disease.
MPS II - IDS
- Hunter syndrome, primarily skeletal abnormalities, myocardial/valvular disease risk.
MPS III - SGSH
- Sanfilippo A/B/C/D, primarily neurological decline without somatic features in
childhood/adolescence.
MPS IVA - GALNS
- Morquio A, skeletal dysplasia, short stature, coronary, valve abnormalities.
MPS VI - ARSB
- Maroteaux-Lamy syndrome, skeletal, ophthalmologic, valvular abnormalities.
Multisystem involvement severity depends upon residual enzyme activities from unique
genetic etiologies across MPS subtypes.
Genetics of MPS
All are autosomal recessive except X-linked MPS II:
- Over 100 pathogenic variants degrade single enzyme activities through truncations,
missense changes impacting stability/catalytic function.
- Variable expressivity from allelic variants, somatic mosaicism impacting severity within
subtypes and between patients.
- Carrier testing assesses risks to relatives, prenatal/preimplantation diagnosis utilized by
carriers for progeny wellbeing.
Establishing causative variants confirms molecular diagnosis facilitating natural history
insights and guiding therapeutic intervention rationale.
Diagnosis
Suspicion stems from characteristic clinical/radiographic features:
- Dysmorphic facies, organomegaly, orthopedic/ocular abnormalities on examination.
- Elevated urinary GAGs by sulfated glycosaminoglycan assay initially screens.
- Enzyme activity assays on leukocytes/fibroblasts confirm specific deficiencies.
- Molecular analysis establishes causative variants in genes encoding deficient enzymes.
Baseline assessment guides establishing molecular diagnosis, prognosis estimation and
intervention planning through multidisciplinary care teams.
Management Strategies
Addressing multisystem involvement holistically:
- Palliative symptom management optimizes outcomes for neurological/non-CNS variants
ineligible for transplantation/ERT.
- Surgical corrections address visual, airway, cardiovascular abnormalities.
- Physical/occupational therapy maintains joint range of motion/mobility.
- Hematopoietic stem cell transplantation halts progression when available.
- Enzyme replacement therapy stabilizes/reverses manifestations in approved subtypes.
- Investigational intrathecal ERT explores neurological variants’ high CSF barriers.
- Preimplantation genetic diagnosis enables unaffected offspring.
Continued advances leveraging pathophysiological understanding promise further therapies
alleviating burdens from these lysosomal disorders’ progressive multi-organ involvement.
Future Directions
Progressing management through precision development:
- Clarifying genotype-phenotype correlations guides intervention timing.
- Advancing newborn screening/early diagnosis before irreversible damage occurs.
- Developing intrathecal/intraventricular ERT delivery across neurological variants.
- Gene therapies approach beyond hematopoietic cell transplantation.
- Disease modeling illuminates modifier genes impacting heterogeneity.
- Biomarkers sensitively monitor disease course under various interventions.
- Designing adjunctive small molecules targeting storage/pathology mechanisms.
Overall, interdisciplinary efforts decoding dysregulated GAG degradation promise refining
management frameworks through rational therapeutic targeting mitigating impact for
individuals living with these progressive multisystem disorders.
Mucopolysaccharidoses (MPS) represent a group of 11 inherited lysosomal storage disorders
arising from deficiencies in enzymes degrading glycosaminoglycans (GAGs). Substrate
accumulation disrupts connective tissues, bones, joints, cartilage, corneas, and organs. Seven
major types (I-VII) exist based upon deficiencies in specific enzymes degrading GAGs.
While variable in severity, progressive multisystem involvement causes major impairments
requiring lifelong care. Newborn screening, hematopoietic stem cell transplantation (HSCT),
and emerging enzyme replacement therapies (ERTs) benefit selected MPS populations.
Further understanding of disease pathogenesis promises novel therapies alleviating
progressive multi-organ involvement characterizing these disorders.
GAG Metabolism and Physiological Roles
Glycosaminoglycans (GAGs) crucially regulate tissue structure, cell signaling, and
development:
- Heparan sulfate, dermatan sulfate, chondroitin sulfate, keratan sulfate compose GAG
chainosities.
- Lysosomal hydrolases degrade GAG disaccharides and monomers for recycling or
excretion.
- Cell surface/extracellular matrix accumulation impacts morphogenesis, inflammatory
responses, growth factor binding when catabolized GAGs accumulate.
Deficient catabolic enzyme activities cause progressive GAG storage clinically evident across
MPS subtypes. Understanding substrate processing deficits rationalizes therapeutic targeting
strategies.
Clinical Features by Enzyme Deficiency
Dependent upon lysosomal deficiency, manifestations involve:
MPS I - IDUA
- Hurler (+/-Hurler-Scheie/Scheie variants), severe organomegaly, facial dysmorphism,
coronary artery, valve disease.
MPS II - IDS
- Hunter syndrome, primarily skeletal abnormalities, myocardial/valvular disease risk.
MPS III - SGSH
- Sanfilippo A/B/C/D, primarily neurological decline without somatic features in
childhood/adolescence.
MPS IVA - GALNS
- Morquio A, skeletal dysplasia, short stature, coronary, valve abnormalities.
MPS VI - ARSB
- Maroteaux-Lamy syndrome, skeletal, ophthalmologic, valvular abnormalities.
Multisystem involvement severity depends upon residual enzyme activities from unique
genetic etiologies across MPS subtypes.
Genetics of MPS
All are autosomal recessive except X-linked MPS II:
- Over 100 pathogenic variants degrade single enzyme activities through truncations,
missense changes impacting stability/catalytic function.
- Variable expressivity from allelic variants, somatic mosaicism impacting severity within
subtypes and between patients.
- Carrier testing assesses risks to relatives, prenatal/preimplantation diagnosis utilized by
carriers for progeny wellbeing.
Establishing causative variants confirms molecular diagnosis facilitating natural history
insights and guiding therapeutic intervention rationale.
Diagnosis
Suspicion stems from characteristic clinical/radiographic features:
- Dysmorphic facies, organomegaly, orthopedic/ocular abnormalities on examination.
- Elevated urinary GAGs by sulfated glycosaminoglycan assay initially screens.
- Enzyme activity assays on leukocytes/fibroblasts confirm specific deficiencies.
- Molecular analysis establishes causative variants in genes encoding deficient enzymes.
Baseline assessment guides establishing molecular diagnosis, prognosis estimation and
intervention planning through multidisciplinary care teams.
Management Strategies
Addressing multisystem involvement holistically:
- Palliative symptom management optimizes outcomes for neurological/non-CNS variants
ineligible for transplantation/ERT.
- Surgical corrections address visual, airway, cardiovascular abnormalities.
- Physical/occupational therapy maintains joint range of motion/mobility.
- Hematopoietic stem cell transplantation halts progression when available.
- Enzyme replacement therapy stabilizes/reverses manifestations in approved subtypes.
- Investigational intrathecal ERT explores neurological variants’ high CSF barriers.
- Preimplantation genetic diagnosis enables unaffected offspring.
Continued advances leveraging pathophysiological understanding promise further therapies
alleviating burdens from these lysosomal disorders’ progressive multi-organ involvement.
Future Directions
Progressing management through precision development:
- Clarifying genotype-phenotype correlations guides intervention timing.
- Advancing newborn screening/early diagnosis before irreversible damage occurs.
- Developing intrathecal/intraventricular ERT delivery across neurological variants.
- Gene therapies approach beyond hematopoietic cell transplantation.
- Disease modeling illuminates modifier genes impacting heterogeneity.
- Biomarkers sensitively monitor disease course under various interventions.
- Designing adjunctive small molecules targeting storage/pathology mechanisms.
Overall, interdisciplinary efforts decoding dysregulated GAG degradation promise refining
management frameworks through rational therapeutic targeting mitigating impact for
individuals living with these progressive multisystem disorders.
Mucopolysaccharidoses (MPS) represent a group of 11 inherited lysosomal storage disorders
arising from deficiencies in enzymes degrading glycosaminoglycans (GAGs). Substrate
accumulation disrupts connective tissues, bones, joints, cartilage, corneas, and organs. Seven
major types (I-VII) exist based upon deficiencies in specific enzymes degrading GAGs.
While variable in severity, progressive multisystem involvement causes major impairments
requiring lifelong care. Newborn screening, hematopoietic stem cell transplantation (HSCT),
and emerging enzyme replacement therapies (ERTs) benefit selected MPS populations.
Further understanding of disease pathogenesis promises novel therapies alleviating
progressive multi-organ involvement characterizing these disorders.
GAG Metabolism and Physiological Roles
Glycosaminoglycans (GAGs) crucially regulate tissue structure, cell signaling, and
development:
- Heparan sulfate, dermatan sulfate, chondroitin sulfate, keratan sulfate compose GAG
chainosities.
- Lysosomal hydrolases degrade GAG disaccharides and monomers for recycling or
excretion.
- Cell surface/extracellular matrix accumulation impacts morphogenesis, inflammatory
responses, growth factor binding when catabolized GAGs accumulate.
Deficient catabolic enzyme activities cause progressive GAG storage clinically evident across
MPS subtypes. Understanding substrate processing deficits rationalizes therapeutic targeting
strategies.
Clinical Features by Enzyme Deficiency
Dependent upon lysosomal deficiency, manifestations involve:
MPS I - IDUA
- Hurler (+/-Hurler-Scheie/Scheie variants), severe organomegaly, facial dysmorphism,
coronary artery, valve disease.
MPS II - IDS
- Hunter syndrome, primarily skeletal abnormalities, myocardial/valvular disease risk.
MPS III - SGSH
- Sanfilippo A/B/C/D, primarily neurological decline without somatic features in
childhood/adolescence.
MPS IVA - GALNS
- Morquio A, skeletal dysplasia, short stature, coronary, valve abnormalities.
MPS VI - ARSB
- Maroteaux-Lamy syndrome, skeletal, ophthalmologic, valvular abnormalities.
Multisystem involvement severity depends upon residual enzyme activities from unique
genetic etiologies across MPS subtypes.
Genetics of MPS
All are autosomal recessive except X-linked MPS II:
- Over 100 pathogenic variants degrade single enzyme activities through truncations,
missense changes impacting stability/catalytic function.
- Variable expressivity from allelic variants, somatic mosaicism impacting severity within
subtypes and between patients.
- Carrier testing assesses risks to relatives, prenatal/preimplantation diagnosis utilized by
carriers for progeny wellbeing.
Establishing causative variants confirms molecular diagnosis facilitating natural history
insights and guiding therapeutic intervention rationale.
Diagnosis
Suspicion stems from characteristic clinical/radiographic features:
- Dysmorphic facies, organomegaly, orthopedic/ocular abnormalities on examination.
- Elevated urinary GAGs by sulfated glycosaminoglycan assay initially screens.
- Enzyme activity assays on leukocytes/fibroblasts confirm specific deficiencies.
- Molecular analysis establishes causative variants in genes encoding deficient enzymes.
Baseline assessment guides establishing molecular diagnosis, prognosis estimation and
intervention planning through multidisciplinary care teams.
Management Strategies
Addressing multisystem involvement holistically:
- Palliative symptom management optimizes outcomes for neurological/non-CNS variants
ineligible for transplantation/ERT.
- Surgical corrections address visual, airway, cardiovascular abnormalities.
- Physical/occupational therapy maintains joint range of motion/mobility.
- Hematopoietic stem cell transplantation halts progression when available.
- Enzyme replacement therapy stabilizes/reverses manifestations in approved subtypes.
- Investigational intrathecal ERT explores neurological variants’ high CSF barriers.
- Preimplantation genetic diagnosis enables unaffected offspring.
Continued advances leveraging pathophysiological understanding promise further therapies
alleviating burdens from these lysosomal disorders’ progressive multi-organ involvement.
Future Directions
Progressing management through precision development:
- Clarifying genotype-phenotype correlations guides intervention timing.
- Advancing newborn screening/early diagnosis before irreversible damage occurs.
- Developing intrathecal/intraventricular ERT delivery across neurological variants.
- Gene therapies approach beyond hematopoietic cell transplantation.
- Disease modeling illuminates modifier genes impacting heterogeneity.
- Biomarkers sensitively monitor disease course under various interventions.
- Designing adjunctive small molecules targeting storage/pathology mechanisms.
Overall, interdisciplinary efforts decoding dysregulated GAG degradation promise refining
management frameworks through rational therapeutic targeting mitigating impact for
individuals living with these progressive multisystem disorders.
Mucopolysaccharidoses (MPS) represent a group of 11 inherited lysosomal storage disorders
arising from deficiencies in enzymes degrading glycosaminoglycans (GAGs). Substrate
accumulation disrupts connective tissues, bones, joints, cartilage, corneas, and organs. Seven
major types (I-VII) exist based upon deficiencies in specific enzymes degrading GAGs.
While variable in severity, progressive multisystem involvement causes major impairments
requiring lifelong care. Newborn screening, hematopoietic stem cell transplantation (HSCT),
and emerging enzyme replacement therapies (ERTs) benefit selected MPS populations.
Further understanding of disease pathogenesis promises novel therapies alleviating
progressive multi-organ involvement characterizing these disorders.
GAG Metabolism and Physiological Roles
Glycosaminoglycans (GAGs) crucially regulate tissue structure, cell signaling, and
development:
- Heparan sulfate, dermatan sulfate, chondroitin sulfate, keratan sulfate compose GAG
chainosities.
- Lysosomal hydrolases degrade GAG disaccharides and monomers for recycling or
excretion.
- Cell surface/extracellular matrix accumulation impacts morphogenesis, inflammatory
responses, growth factor binding when catabolized GAGs accumulate.
Deficient catabolic enzyme activities cause progressive GAG storage clinically evident across
MPS subtypes. Understanding substrate processing deficits rationalizes therapeutic targeting
strategies.
Clinical Features by Enzyme Deficiency
Dependent upon lysosomal deficiency, manifestations involve:
MPS I - IDUA
- Hurler (+/-Hurler-Scheie/Scheie variants), severe organomegaly, facial dysmorphism,
coronary artery, valve disease.
MPS II - IDS
- Hunter syndrome, primarily skeletal abnormalities, myocardial/valvular disease risk.
MPS III - SGSH
- Sanfilippo A/B/C/D, primarily neurological decline without somatic features in
childhood/adolescence.
MPS IVA - GALNS
- Morquio A, skeletal dysplasia, short stature, coronary, valve abnormalities.
MPS VI - ARSB
- Maroteaux-Lamy syndrome, skeletal, ophthalmologic, valvular abnormalities.
Multisystem involvement severity depends upon residual enzyme activities from unique
genetic etiologies across MPS subtypes.
Genetics of MPS
All are autosomal recessive except X-linked MPS II:
- Over 100 pathogenic variants degrade single enzyme activities through truncations,
missense changes impacting stability/catalytic function.
- Variable expressivity from allelic variants, somatic mosaicism impacting severity within
subtypes and between patients.
- Carrier testing assesses risks to relatives, prenatal/preimplantation diagnosis utilized by
carriers for progeny wellbeing.
Establishing causative variants confirms molecular diagnosis facilitating natural history
insights and guiding therapeutic intervention rationale.
Diagnosis
Suspicion stems from characteristic clinical/radiographic features:
- Dysmorphic facies, organomegaly, orthopedic/ocular abnormalities on examination.
- Elevated urinary GAGs by sulfated glycosaminoglycan assay initially screens.
- Enzyme activity assays on leukocytes/fibroblasts confirm specific deficiencies.
- Molecular analysis establishes causative variants in genes encoding deficient enzymes.
Baseline assessment guides establishing molecular diagnosis, prognosis estimation and
intervention planning through multidisciplinary care teams.
Management Strategies
Addressing multisystem involvement holistically:
- Palliative symptom management optimizes outcomes for neurological/non-CNS variants
ineligible for transplantation/ERT.
- Surgical corrections address visual, airway, cardiovascular abnormalities.
- Physical/occupational therapy maintains joint range of motion/mobility.
- Hematopoietic stem cell transplantation halts progression when available.
- Enzyme replacement therapy stabilizes/reverses manifestations in approved subtypes.
- Investigational intrathecal ERT explores neurological variants’ high CSF barriers.
- Preimplantation genetic diagnosis enables unaffected offspring.
Continued advances leveraging pathophysiological understanding promise further therapies
alleviating burdens from these lysosomal disorders’ progressive multi-organ involvement.
Future Directions
Progressing management through precision development:
- Clarifying genotype-phenotype correlations guides intervention timing.
- Advancing newborn screening/early diagnosis before irreversible damage occurs.
- Developing intrathecal/intraventricular ERT delivery across neurological variants.
- Gene therapies approach beyond hematopoietic cell transplantation.
- Disease modeling illuminates modifier genes impacting heterogeneity.
- Biomarkers sensitively monitor disease course under various interventions.
- Designing adjunctive small molecules targeting storage/pathology mechanisms.
Overall, interdisciplinary efforts decoding dysregulated GAG degradation promise refining
management frameworks through rational therapeutic targeting mitigating impact for
individuals living with these progressive multisystem disorders.
Mucopolysaccharidoses (MPS) represent a group of 11 inherited lysosomal storage disorders
arising from deficiencies in enzymes degrading glycosaminoglycans (GAGs). Substrate
accumulation disrupts connective tissues, bones, joints, cartilage, corneas, and organs. Seven
major types (I-VII) exist based upon deficiencies in specific enzymes degrading GAGs.
While variable in severity, progressive multisystem involvement causes major impairments
requiring lifelong care. Newborn screening, hematopoietic stem cell transplantation (HSCT),
and emerging enzyme replacement therapies (ERTs) benefit selected MPS populations.
Further understanding of disease pathogenesis promises novel therapies alleviating
progressive multi-organ involvement characterizing these disorders.
GAG Metabolism and Physiological Roles
Glycosaminoglycans (GAGs) crucially regulate tissue structure, cell signaling, and
development:
- Heparan sulfate, dermatan sulfate, chondroitin sulfate, keratan sulfate compose GAG
chainosities.
- Lysosomal hydrolases degrade GAG disaccharides and monomers for recycling or
excretion.
- Cell surface/extracellular matrix accumulation impacts morphogenesis, inflammatory
responses, growth factor binding when catabolized GAGs accumulate.
Deficient catabolic enzyme activities cause progressive GAG storage clinically evident across
MPS subtypes. Understanding substrate processing deficits rationalizes therapeutic targeting
strategies.
Clinical Features by Enzyme Deficiency
Dependent upon lysosomal deficiency, manifestations involve:
MPS I - IDUA
- Hurler (+/-Hurler-Scheie/Scheie variants), severe organomegaly, facial dysmorphism,
coronary artery, valve disease.
MPS II - IDS
- Hunter syndrome, primarily skeletal abnormalities, myocardial/valvular disease risk.
MPS III - SGSH
- Sanfilippo A/B/C/D, primarily neurological decline without somatic features in
childhood/adolescence.
MPS IVA - GALNS
- Morquio A, skeletal dysplasia, short stature, coronary, valve abnormalities.
MPS VI - ARSB
- Maroteaux-Lamy syndrome, skeletal, ophthalmologic, valvular abnormalities.
Multisystem involvement severity depends upon residual enzyme activities from unique
genetic etiologies across MPS subtypes.
Genetics of MPS
All are autosomal recessive except X-linked MPS II:
- Over 100 pathogenic variants degrade single enzyme activities through truncations,
missense changes impacting stability/catalytic function.
- Variable expressivity from allelic variants, somatic mosaicism impacting severity within
subtypes and between patients.
- Carrier testing assesses risks to relatives, prenatal/preimplantation diagnosis utilized by
carriers for progeny wellbeing.
Establishing causative variants confirms molecular diagnosis facilitating natural history
insights and guiding therapeutic intervention rationale.
Diagnosis
Suspicion stems from characteristic clinical/radiographic features:
- Dysmorphic facies, organomegaly, orthopedic/ocular abnormalities on examination.
- Elevated urinary GAGs by sulfated glycosaminoglycan assay initially screens.
- Enzyme activity assays on leukocytes/fibroblasts confirm specific deficiencies.
- Molecular analysis establishes causative variants in genes encoding deficient enzymes.
Baseline assessment guides establishing molecular diagnosis, prognosis estimation and
intervention planning through multidisciplinary care teams.
Management Strategies
Addressing multisystem involvement holistically:
- Palliative symptom management optimizes outcomes for neurological/non-CNS variants
ineligible for transplantation/ERT.
- Surgical corrections address visual, airway, cardiovascular abnormalities.
- Physical/occupational therapy maintains joint range of motion/mobility.
- Hematopoietic stem cell transplantation halts progression when available.
- Enzyme replacement therapy stabilizes/reverses manifestations in approved subtypes.
- Investigational intrathecal ERT explores neurological variants’ high CSF barriers.
- Preimplantation genetic diagnosis enables unaffected offspring.
Continued advances leveraging pathophysiological understanding promise further therapies
alleviating burdens from these lysosomal disorders’ progressive multi-organ involvement.
Future Directions
Progressing management through precision development:
- Clarifying genotype-phenotype correlations guides intervention timing.
- Advancing newborn screening/early diagnosis before irreversible damage occurs.
- Developing intrathecal/intraventricular ERT delivery across neurological variants.
- Gene therapies approach beyond hematopoietic cell transplantation.
- Disease modeling illuminates modifier genes impacting heterogeneity.
- Biomarkers sensitively monitor disease course under various interventions.
- Designing adjunctive small molecules targeting storage/pathology mechanisms.
Overall, interdisciplinary efforts decoding dysregulated GAG degradation promise refining
management frameworks through rational therapeutic targeting mitigating impact for
individuals living with these progressive multisystem disorders.
Mucopolysaccharidoses (MPS) represent a group of 11 inherited lysosomal storage disorders
arising from deficiencies in enzymes degrading glycosaminoglycans (GAGs). Substrate
accumulation disrupts connective tissues, bones, joints, cartilage, corneas, and organs. Seven
major types (I-VII) exist based upon deficiencies in specific enzymes degrading GAGs.
While variable in severity, progressive multisystem involvement causes major impairments
requiring lifelong care. Newborn screening, hematopoietic stem cell transplantation (HSCT),
and emerging enzyme replacement therapies (ERTs) benefit selected MPS populations.
Further understanding of disease pathogenesis promises novel therapies alleviating
progressive multi-organ involvement characterizing these disorders.
GAG Metabolism and Physiological Roles
Glycosaminoglycans (GAGs) crucially regulate tissue structure, cell signaling, and
development:
- Heparan sulfate, dermatan sulfate, chondroitin sulfate, keratan sulfate compose GAG
chainosities.
- Lysosomal hydrolases degrade GAG disaccharides and monomers for recycling or
excretion.
- Cell surface/extracellular matrix accumulation impacts morphogenesis, inflammatory
responses, growth factor binding when catabolized GAGs accumulate.
Deficient catabolic enzyme activities cause progressive GAG storage clinically evident across
MPS subtypes. Understanding substrate processing deficits rationalizes therapeutic targeting
strategies.
Clinical Features by Enzyme Deficiency
Dependent upon lysosomal deficiency, manifestations involve:
MPS I - IDUA
- Hurler (+/-Hurler-Scheie/Scheie variants), severe organomegaly, facial dysmorphism,
coronary artery, valve disease.
MPS II - IDS
- Hunter syndrome, primarily skeletal abnormalities, myocardial/valvular disease risk.
MPS III - SGSH
- Sanfilippo A/B/C/D, primarily neurological decline without somatic features in
childhood/adolescence.
MPS IVA - GALNS
- Morquio A, skeletal dysplasia, short stature, coronary, valve abnormalities.
MPS VI - ARSB
- Maroteaux-Lamy syndrome, skeletal, ophthalmologic, valvular abnormalities.
Multisystem involvement severity depends upon residual enzyme activities from unique
genetic etiologies across MPS subtypes.
Genetics of MPS
All are autosomal recessive except X-linked MPS II:
- Over 100 pathogenic variants degrade single enzyme activities through truncations,
missense changes impacting stability/catalytic function.
- Variable expressivity from allelic variants, somatic mosaicism impacting severity within
subtypes and between patients.
- Carrier testing assesses risks to relatives, prenatal/preimplantation diagnosis utilized by
carriers for progeny wellbeing.
Establishing causative variants confirms molecular diagnosis facilitating natural history
insights and guiding therapeutic intervention rationale.
Diagnosis
Suspicion stems from characteristic clinical/radiographic features:
- Dysmorphic facies, organomegaly, orthopedic/ocular abnormalities on examination.
- Elevated urinary GAGs by sulfated glycosaminoglycan assay initially screens.
- Enzyme activity assays on leukocytes/fibroblasts confirm specific deficiencies.
- Molecular analysis establishes causative variants in genes encoding deficient enzymes.
Baseline assessment guides establishing molecular diagnosis, prognosis estimation and
intervention planning through multidisciplinary care teams.
Management Strategies
Addressing multisystem involvement holistically:
- Palliative symptom management optimizes outcomes for neurological/non-CNS variants
ineligible for transplantation/ERT.
- Surgical corrections address visual, airway, cardiovascular abnormalities.
- Physical/occupational therapy maintains joint range of motion/mobility.
- Hematopoietic stem cell transplantation halts progression when available.
- Enzyme replacement therapy stabilizes/reverses manifestations in approved subtypes.
- Investigational intrathecal ERT explores neurological variants’ high CSF barriers.
- Preimplantation genetic diagnosis enables unaffected offspring.
Continued advances leveraging pathophysiological understanding promise further therapies
alleviating burdens from these lysosomal disorders’ progressive multi-organ involvement.
Future Directions
Progressing management through precision development:
- Clarifying genotype-phenotype correlations guides intervention timing.
- Advancing newborn screening/early diagnosis before irreversible damage occurs.
- Developing intrathecal/intraventricular ERT delivery across neurological variants.
- Gene therapies approach beyond hematopoietic cell transplantation.
- Disease modeling illuminates modifier genes impacting heterogeneity.
- Biomarkers sensitively monitor disease course under various interventions.
- Designing adjunctive small molecules targeting storage/pathology mechanisms.
Overall, interdisciplinary efforts decoding dysregulated GAG degradation promise refining
management frameworks through rational therapeutic targeting mitigating impact for
individuals living with these progressive multisystem disorders.
Mucopolysaccharidoses (MPS) represent a group of 11 inherited lysosomal storage disorders
arising from deficiencies in enzymes degrading glycosaminoglycans (GAGs). Substrate
accumulation disrupts connective tissues, bones, joints, cartilage, corneas, and organs. Seven
major types (I-VII) exist based upon deficiencies in specific enzymes degrading GAGs.
While variable in severity, progressive multisystem involvement causes major impairments
requiring lifelong care. Newborn screening, hematopoietic stem cell transplantation (HSCT),
and emerging enzyme replacement therapies (ERTs) benefit selected MPS populations.
Further understanding of disease pathogenesis promises novel therapies alleviating
progressive multi-organ involvement characterizing these disorders.
GAG Metabolism and Physiological Roles
Glycosaminoglycans (GAGs) crucially regulate tissue structure, cell signaling, and
development:
- Heparan sulfate, dermatan sulfate, chondroitin sulfate, keratan sulfate compose GAG
chainosities.
- Lysosomal hydrolases degrade GAG disaccharides and monomers for recycling or
excretion.
- Cell surface/extracellular matrix accumulation impacts morphogenesis, inflammatory
responses, growth factor binding when catabolized GAGs accumulate.
Deficient catabolic enzyme activities cause progressive GAG storage clinically evident across
MPS subtypes. Understanding substrate processing deficits rationalizes therapeutic targeting
strategies.
Clinical Features by Enzyme Deficiency
Dependent upon lysosomal deficiency, manifestations involve:
MPS I - IDUA
- Hurler (+/-Hurler-Scheie/Scheie variants), severe organomegaly, facial dysmorphism,
coronary artery, valve disease.
MPS II - IDS
- Hunter syndrome, primarily skeletal abnormalities, myocardial/valvular disease risk.
MPS III - SGSH
- Sanfilippo A/B/C/D, primarily neurological decline without somatic features in
childhood/adolescence.
MPS IVA - GALNS
- Morquio A, skeletal dysplasia, short stature, coronary, valve abnormalities.
MPS VI - ARSB
- Maroteaux-Lamy syndrome, skeletal, ophthalmologic, valvular abnormalities.
Multisystem involvement severity depends upon residual enzyme activities from unique
genetic etiologies across MPS subtypes.
Genetics of MPS
All are autosomal recessive except X-linked MPS II:
- Over 100 pathogenic variants degrade single enzyme activities through truncations,
missense changes impacting stability/catalytic function.
- Variable expressivity from allelic variants, somatic mosaicism impacting severity within
subtypes and between patients.
- Carrier testing assesses risks to relatives, prenatal/preimplantation diagnosis utilized by
carriers for progeny wellbeing.
Establishing causative variants confirms molecular diagnosis facilitating natural history
insights and guiding therapeutic intervention rationale.
Diagnosis
Suspicion stems from characteristic clinical/radiographic features:
- Dysmorphic facies, organomegaly, orthopedic/ocular abnormalities on examination.
- Elevated urinary GAGs by sulfated glycosaminoglycan assay initially screens.
- Enzyme activity assays on leukocytes/fibroblasts confirm specific deficiencies.
- Molecular analysis establishes causative variants in genes encoding deficient enzymes.
Baseline assessment guides establishing molecular diagnosis, prognosis estimation and
intervention planning through multidisciplinary care teams.
Management Strategies
Addressing multisystem involvement holistically:
- Palliative symptom management optimizes outcomes for neurological/non-CNS variants
ineligible for transplantation/ERT.
- Surgical corrections address visual, airway, cardiovascular abnormalities.
- Physical/occupational therapy maintains joint range of motion/mobility.
- Hematopoietic stem cell transplantation halts progression when available.
- Enzyme replacement therapy stabilizes/reverses manifestations in approved subtypes.
- Investigational intrathecal ERT explores neurological variants’ high CSF barriers.
- Preimplantation genetic diagnosis enables unaffected offspring.
Continued advances leveraging pathophysiological understanding promise further therapies
alleviating burdens from these lysosomal disorders’ progressive multi-organ involvement.
Future Directions
Progressing management through precision development:
- Clarifying genotype-phenotype correlations guides intervention timing.
- Advancing newborn screening/early diagnosis before irreversible damage occurs.
- Developing intrathecal/intraventricular ERT delivery across neurological variants.
- Gene therapies approach beyond hematopoietic cell transplantation.
- Disease modeling illuminates modifier genes impacting heterogeneity.
- Biomarkers sensitively monitor disease course under various interventions.
- Designing adjunctive small molecules targeting storage/pathology mechanisms.
Overall, interdisciplinary efforts decoding dysregulated GAG degradation promise refining
management frameworks through rational therapeutic targeting mitigating impact for
individuals living with these progressive multisystem disorders.
Mucopolysaccharidoses (MPS) represent a group of 11 inherited lysosomal storage disorders
arising from deficiencies in enzymes degrading glycosaminoglycans (GAGs). Substrate
accumulation disrupts connective tissues, bones, joints, cartilage, corneas, and organs. Seven
major types (I-VII) exist based upon deficiencies in specific enzymes degrading GAGs.
While variable in severity, progressive multisystem involvement causes major impairments
requiring lifelong care. Newborn screening, hematopoietic stem cell transplantation (HSCT),
and emerging enzyme replacement therapies (ERTs) benefit selected MPS populations.
Further understanding of disease pathogenesis promises novel therapies alleviating
progressive multi-organ involvement characterizing these disorders.
GAG Metabolism and Physiological Roles
Glycosaminoglycans (GAGs) crucially regulate tissue structure, cell signaling, and
development:
- Heparan sulfate, dermatan sulfate, chondroitin sulfate, keratan sulfate compose GAG
chainosities.
- Lysosomal hydrolases degrade GAG disaccharides and monomers for recycling or
excretion.
- Cell surface/extracellular matrix accumulation impacts morphogenesis, inflammatory
responses, growth factor binding when catabolized GAGs accumulate.
Deficient catabolic enzyme activities cause progressive GAG storage clinically evident across
MPS subtypes. Understanding substrate processing deficits rationalizes therapeutic targeting
strategies.
Clinical Features by Enzyme Deficiency
Dependent upon lysosomal deficiency, manifestations involve:
MPS I - IDUA
- Hurler (+/-Hurler-Scheie/Scheie variants), severe organomegaly, facial dysmorphism,
coronary artery, valve disease.
MPS II - IDS
- Hunter syndrome, primarily skeletal abnormalities, myocardial/valvular disease risk.
MPS III - SGSH
- Sanfilippo A/B/C/D, primarily neurological decline without somatic features in
childhood/adolescence.
MPS IVA - GALNS
- Morquio A, skeletal dysplasia, short stature, coronary, valve abnormalities.
MPS VI - ARSB
- Maroteaux-Lamy syndrome, skeletal, ophthalmologic, valvular abnormalities.
Multisystem involvement severity depends upon residual enzyme activities from unique
genetic etiologies across MPS subtypes.
Genetics of MPS
All are autosomal recessive except X-linked MPS II:
- Over 100 pathogenic variants degrade single enzyme activities through truncations,
missense changes impacting stability/catalytic function.
- Variable expressivity from allelic variants, somatic mosaicism impacting severity within
subtypes and between patients.
- Carrier testing assesses risks to relatives, prenatal/preimplantation diagnosis utilized by
carriers for progeny wellbeing.
Establishing causative variants confirms molecular diagnosis facilitating natural history
insights and guiding therapeutic intervention rationale.
Diagnosis
Suspicion stems from characteristic clinical/radiographic features:
- Dysmorphic facies, organomegaly, orthopedic/ocular abnormalities on examination.
- Elevated urinary GAGs by sulfated glycosaminoglycan assay initially screens.
- Enzyme activity assays on leukocytes/fibroblasts confirm specific deficiencies.
- Molecular analysis establishes causative variants in genes encoding deficient enzymes.
Baseline assessment guides establishing molecular diagnosis, prognosis estimation and
intervention planning through multidisciplinary care teams.
Management Strategies
Addressing multisystem involvement holistically:
- Palliative symptom management optimizes outcomes for neurological/non-CNS variants
ineligible for transplantation/ERT.
- Surgical corrections address visual, airway, cardiovascular abnormalities.
- Physical/occupational therapy maintains joint range of motion/mobility.
- Hematopoietic stem cell transplantation halts progression when available.
- Enzyme replacement therapy stabilizes/reverses manifestations in approved subtypes.
- Investigational intrathecal ERT explores neurological variants’ high CSF barriers.
- Preimplantation genetic diagnosis enables unaffected offspring.
Continued advances leveraging pathophysiological understanding promise further therapies
alleviating burdens from these lysosomal disorders’ progressive multi-organ involvement.
Future Directions
Progressing management through precision development:
- Clarifying genotype-phenotype correlations guides intervention timing.
- Advancing newborn screening/early diagnosis before irreversible damage occurs.
- Developing intrathecal/intraventricular ERT delivery across neurological variants.
- Gene therapies approach beyond hematopoietic cell transplantation.
- Disease modeling illuminates modifier genes impacting heterogeneity.
- Biomarkers sensitively monitor disease course under various interventions.
- Designing adjunctive small molecules targeting storage/pathology mechanisms.
Overall, interdisciplinary efforts decoding dysregulated GAG degradation promise refining
management frameworks through rational therapeutic targeting mitigating impact for
individuals living with these progressive multisystem disorders.
Mucopolysaccharidoses (MPS) represent a group of 11 inherited lysosomal storage disorders
arising from deficiencies in enzymes degrading glycosaminoglycans (GAGs). Substrate
accumulation disrupts connective tissues, bones, joints, cartilage, corneas, and organs. Seven
major types (I-VII) exist based upon deficiencies in specific enzymes degrading GAGs.
While variable in severity, progressive multisystem involvement causes major impairments
requiring lifelong care. Newborn screening, hematopoietic stem cell transplantation (HSCT),
and emerging enzyme replacement therapies (ERTs) benefit selected MPS populations.
Further understanding of disease pathogenesis promises novel therapies alleviating
progressive multi-organ involvement characterizing these disorders.
GAG Metabolism and Physiological Roles
Glycosaminoglycans (GAGs) crucially regulate tissue structure, cell signaling, and
development:
- Heparan sulfate, dermatan sulfate, chondroitin sulfate, keratan sulfate compose GAG
chainosities.
- Lysosomal hydrolases degrade GAG disaccharides and monomers for recycling or
excretion.
- Cell surface/extracellular matrix accumulation impacts morphogenesis, inflammatory
responses, growth factor binding when catabolized GAGs accumulate.
Deficient catabolic enzyme activities cause progressive GAG storage clinically evident across
MPS subtypes. Understanding substrate processing deficits rationalizes therapeutic targeting
strategies.
Clinical Features by Enzyme Deficiency
Dependent upon lysosomal deficiency, manifestations involve:
MPS I - IDUA
- Hurler (+/-Hurler-Scheie/Scheie variants), severe organomegaly, facial dysmorphism,
coronary artery, valve disease.
MPS II - IDS
- Hunter syndrome, primarily skeletal abnormalities, myocardial/valvular disease risk.
MPS III - SGSH
- Sanfilippo A/B/C/D, primarily neurological decline without somatic features in
childhood/adolescence.
MPS IVA - GALNS
- Morquio A, skeletal dysplasia, short stature, coronary, valve abnormalities.
MPS VI - ARSB
- Maroteaux-Lamy syndrome, skeletal, ophthalmologic, valvular abnormalities.
Multisystem involvement severity depends upon residual enzyme activities from unique
genetic etiologies across MPS subtypes.
Genetics of MPS
All are autosomal recessive except X-linked MPS II:
- Over 100 pathogenic variants degrade single enzyme activities through truncations,
missense changes impacting stability/catalytic function.
- Variable expressivity from allelic variants, somatic mosaicism impacting severity within
subtypes and between patients.
- Carrier testing assesses risks to relatives, prenatal/preimplantation diagnosis utilized by
carriers for progeny wellbeing.
Establishing causative variants confirms molecular diagnosis facilitating natural history
insights and guiding therapeutic intervention rationale.
Diagnosis
Suspicion stems from characteristic clinical/radiographic features:
- Dysmorphic facies, organomegaly, orthopedic/ocular abnormalities on examination.
- Elevated urinary GAGs by sulfated glycosaminoglycan assay initially screens.
- Enzyme activity assays on leukocytes/fibroblasts confirm specific deficiencies.
- Molecular analysis establishes causative variants in genes encoding deficient enzymes.
Baseline assessment guides establishing molecular diagnosis, prognosis estimation and
intervention planning through multidisciplinary care teams.
Management Strategies
Addressing multisystem involvement holistically:
- Palliative symptom management optimizes outcomes for neurological/non-CNS variants
ineligible for transplantation/ERT.
- Surgical corrections address visual, airway, cardiovascular abnormalities.
- Physical/occupational therapy maintains joint range of motion/mobility.
- Hematopoietic stem cell transplantation halts progression when available.
- Enzyme replacement therapy stabilizes/reverses manifestations in approved subtypes.
- Investigational intrathecal ERT explores neurological variants’ high CSF barriers.
- Preimplantation genetic diagnosis enables unaffected offspring.
Continued advances leveraging pathophysiological understanding promise further therapies
alleviating burdens from these lysosomal disorders’ progressive multi-organ involvement.
Future Directions
Progressing management through precision development:
- Clarifying genotype-phenotype correlations guides intervention timing.
- Advancing newborn screening/early diagnosis before irreversible damage occurs.
- Developing intrathecal/intraventricular ERT delivery across neurological variants.
- Gene therapies approach beyond hematopoietic cell transplantation.
- Disease modeling illuminates modifier genes impacting heterogeneity.
- Biomarkers sensitively monitor disease course under various interventions.
- Designing adjunctive small molecules targeting storage/pathology mechanisms.
Overall, interdisciplinary efforts decoding dysregulated GAG degradation promise refining
management frameworks through rational therapeutic targeting mitigating impact for
individuals living with these progressive multisystem disorders.
Mucopolysaccharidoses (MPS) represent a group of 11 inherited lysosomal storage disorders
arising from deficiencies in enzymes degrading glycosaminoglycans (GAGs). Substrate
accumulation disrupts connective tissues, bones, joints, cartilage, corneas, and organs. Seven
major types (I-VII) exist based upon deficiencies in specific enzymes degrading GAGs.
While variable in severity, progressive multisystem involvement causes major impairments
requiring lifelong care. Newborn screening, hematopoietic stem cell transplantation (HSCT),
and emerging enzyme replacement therapies (ERTs) benefit selected MPS populations.
Further understanding of disease pathogenesis promises novel therapies alleviating
progressive multi-organ involvement characterizing these disorders.
GAG Metabolism and Physiological Roles
Glycosaminoglycans (GAGs) crucially regulate tissue structure, cell signaling, and
development:
- Heparan sulfate, dermatan sulfate, chondroitin sulfate, keratan sulfate compose GAG
chainosities.
- Lysosomal hydrolases degrade GAG disaccharides and monomers for recycling or
excretion.
- Cell surface/extracellular matrix accumulation impacts morphogenesis, inflammatory
responses, growth factor binding when catabolized GAGs accumulate.
Deficient catabolic enzyme activities cause progressive GAG storage clinically evident across
MPS subtypes. Understanding substrate processing deficits rationalizes therapeutic targeting
strategies.
Clinical Features by Enzyme Deficiency
Dependent upon lysosomal deficiency, manifestations involve:
MPS I - IDUA
- Hurler (+/-Hurler-Scheie/Scheie variants), severe organomegaly, facial dysmorphism,
coronary artery, valve disease.
MPS II - IDS
- Hunter syndrome, primarily skeletal abnormalities, myocardial/valvular disease risk.
MPS III - SGSH
- Sanfilippo A/B/C/D, primarily neurological decline without somatic features in
childhood/adolescence.
MPS IVA - GALNS
- Morquio A, skeletal dysplasia, short stature, coronary, valve abnormalities.
MPS VI - ARSB
- Maroteaux-Lamy syndrome, skeletal, ophthalmologic, valvular abnormalities.
Multisystem involvement severity depends upon residual enzyme activities from unique
genetic etiologies across MPS subtypes.
Genetics of MPS
All are autosomal recessive except X-linked MPS II:
- Over 100 pathogenic variants degrade single enzyme activities through truncations,
missense changes impacting stability/catalytic function.
- Variable expressivity from allelic variants, somatic mosaicism impacting severity within
subtypes and between patients.
- Carrier testing assesses risks to relatives, prenatal/preimplantation diagnosis utilized by
carriers for progeny wellbeing.
Establishing causative variants confirms molecular diagnosis facilitating natural history
insights and guiding therapeutic intervention rationale.
Diagnosis
Suspicion stems from characteristic clinical/radiographic features:
- Dysmorphic facies, organomegaly, orthopedic/ocular abnormalities on examination.
- Elevated urinary GAGs by sulfated glycosaminoglycan assay initially screens.
- Enzyme activity assays on leukocytes/fibroblasts confirm specific deficiencies.
- Molecular analysis establishes causative variants in genes encoding deficient enzymes.
Baseline assessment guides establishing molecular diagnosis, prognosis estimation and
intervention planning through multidisciplinary care teams.
Management Strategies
Addressing multisystem involvement holistically:
- Palliative symptom management optimizes outcomes for neurological/non-CNS variants
ineligible for transplantation/ERT.
- Surgical corrections address visual, airway, cardiovascular abnormalities.
- Physical/occupational therapy maintains joint range of motion/mobility.
- Hematopoietic stem cell transplantation halts progression when available.
- Enzyme replacement therapy stabilizes/reverses manifestations in approved subtypes.
- Investigational intrathecal ERT explores neurological variants’ high CSF barriers.
- Preimplantation genetic diagnosis enables unaffected offspring.
Continued advances leveraging pathophysiological understanding promise further therapies
alleviating burdens from these lysosomal disorders’ progressive multi-organ involvement.
Future Directions
Progressing management through precision development:
- Clarifying genotype-phenotype correlations guides intervention timing.
- Advancing newborn screening/early diagnosis before irreversible damage occurs.
- Developing intrathecal/intraventricular ERT delivery across neurological variants.
- Gene therapies approach beyond hematopoietic cell transplantation.
- Disease modeling illuminates modifier genes impacting heterogeneity.
- Biomarkers sensitively monitor disease course under various interventions.
- Designing adjunctive small molecules targeting storage/pathology mechanisms.
Overall, interdisciplinary efforts decoding dysregulated GAG degradation promise refining
management frameworks through rational therapeutic targeting mitigating impact for
individuals living with these progressive multisystem disorders.
Mucopolysaccharidoses (MPS) represent a group of 11 inherited lysosomal storage disorders
arising from deficiencies in enzymes degrading glycosaminoglycans (GAGs). Substrate
accumulation disrupts connective tissues, bones, joints, cartilage, corneas, and organs. Seven
major types (I-VII) exist based upon deficiencies in specific enzymes degrading GAGs.
While variable in severity, progressive multisystem involvement causes major impairments
requiring lifelong care. Newborn screening, hematopoietic stem cell transplantation (HSCT),
and emerging enzyme replacement therapies (ERTs) benefit selected MPS populations.
Further understanding of disease pathogenesis promises novel therapies alleviating
progressive multi-organ involvement characterizing these disorders.
GAG Metabolism and Physiological Roles
Glycosaminoglycans (GAGs) crucially regulate tissue structure, cell signaling, and
development:
- Heparan sulfate, dermatan sulfate, chondroitin sulfate, keratan sulfate compose GAG
chainosities.
- Lysosomal hydrolases degrade GAG disaccharides and monomers for recycling or
excretion.
- Cell surface/extracellular matrix accumulation impacts morphogenesis, inflammatory
responses, growth factor binding when catabolized GAGs accumulate.
Deficient catabolic enzyme activities cause progressive GAG storage clinically evident across
MPS subtypes. Understanding substrate processing deficits rationalizes therapeutic targeting
strategies.
Clinical Features by Enzyme Deficiency
Dependent upon lysosomal deficiency, manifestations involve:
MPS I - IDUA
- Hurler (+/-Hurler-Scheie/Scheie variants), severe organomegaly, facial dysmorphism,
coronary artery, valve disease.
MPS II - IDS
- Hunter syndrome, primarily skeletal abnormalities, myocardial/valvular disease risk.
MPS III - SGSH
- Sanfilippo A/B/C/D, primarily neurological decline without somatic features in
childhood/adolescence.
MPS IVA - GALNS
- Morquio A, skeletal dysplasia, short stature, coronary, valve abnormalities.
MPS VI - ARSB
- Maroteaux-Lamy syndrome, skeletal, ophthalmologic, valvular abnormalities.
Multisystem involvement severity depends upon residual enzyme activities from unique
genetic etiologies across MPS subtypes.
Genetics of MPS
All are autosomal recessive except X-linked MPS II:
- Over 100 pathogenic variants degrade single enzyme activities through truncations,
missense changes impacting stability/catalytic function.
- Variable expressivity from allelic variants, somatic mosaicism impacting severity within
subtypes and between patients.
- Carrier testing assesses risks to relatives, prenatal/preimplantation diagnosis utilized by
carriers for progeny wellbeing.
Establishing causative variants confirms molecular diagnosis facilitating natural history
insights and guiding therapeutic intervention rationale.
Diagnosis
Suspicion stems from characteristic clinical/radiographic features:
- Dysmorphic facies, organomegaly, orthopedic/ocular abnormalities on examination.
- Elevated urinary GAGs by sulfated glycosaminoglycan assay initially screens.
- Enzyme activity assays on leukocytes/fibroblasts confirm specific deficiencies.
- Molecular analysis establishes causative variants in genes encoding deficient enzymes.
Baseline assessment guides establishing molecular diagnosis, prognosis estimation and
intervention planning through multidisciplinary care teams.
Management Strategies
Addressing multisystem involvement holistically:
- Palliative symptom management optimizes outcomes for neurological/non-CNS variants
ineligible for transplantation/ERT.
- Surgical corrections address visual, airway, cardiovascular abnormalities.
- Physical/occupational therapy maintains joint range of motion/mobility.
- Hematopoietic stem cell transplantation halts progression when available.
- Enzyme replacement therapy stabilizes/reverses manifestations in approved subtypes.
- Investigational intrathecal ERT explores neurological variants’ high CSF barriers.
- Preimplantation genetic diagnosis enables unaffected offspring.
Continued advances leveraging pathophysiological understanding promise further therapies
alleviating burdens from these lysosomal disorders’ progressive multi-organ involvement.
Future Directions
Progressing management through precision development:
- Clarifying genotype-phenotype correlations guides intervention timing.
- Advancing newborn screening/early diagnosis before irreversible damage occurs.
- Developing intrathecal/intraventricular ERT delivery across neurological variants.
- Gene therapies approach beyond hematopoietic cell transplantation.
- Disease modeling illuminates modifier genes impacting heterogeneity.
- Biomarkers sensitively monitor disease course under various interventions.
- Designing adjunctive small molecules targeting storage/pathology mechanisms.
Overall, interdisciplinary efforts decoding dysregulated GAG degradation promise refining
management frameworks through rational therapeutic targeting mitigating impact for
individuals living with these progressive multisystem disorders.
Mucopolysaccharidoses (MPS) represent a group of 11 inherited lysosomal storage disorders
arising from deficiencies in enzymes degrading glycosaminoglycans (GAGs). Substrate
accumulation disrupts connective tissues, bones, joints, cartilage, corneas, and organs. Seven
major types (I-VII) exist based upon deficiencies in specific enzymes degrading GAGs.
While variable in severity, progressive multisystem involvement causes major impairments
requiring lifelong care. Newborn screening, hematopoietic stem cell transplantation (HSCT),
and emerging enzyme replacement therapies (ERTs) benefit selected MPS populations.
Further understanding of disease pathogenesis promises novel therapies alleviating
progressive multi-organ involvement characterizing these disorders.
GAG Metabolism and Physiological Roles
Glycosaminoglycans (GAGs) crucially regulate tissue structure, cell signaling, and
development:
- Heparan sulfate, dermatan sulfate, chondroitin sulfate, keratan sulfate compose GAG
chainosities.
- Lysosomal hydrolases degrade GAG disaccharides and monomers for recycling or
excretion.
- Cell surface/extracellular matrix accumulation impacts morphogenesis, inflammatory
responses, growth factor binding when catabolized GAGs accumulate.
Deficient catabolic enzyme activities cause progressive GAG storage clinically evident across
MPS subtypes. Understanding substrate processing deficits rationalizes therapeutic targeting
strategies.
Clinical Features by Enzyme Deficiency
Dependent upon lysosomal deficiency, manifestations involve:
MPS I - IDUA
- Hurler (+/-Hurler-Scheie/Scheie variants), severe organomegaly, facial dysmorphism,
coronary artery, valve disease.
MPS II - IDS
- Hunter syndrome, primarily skeletal abnormalities, myocardial/valvular disease risk.
MPS III - SGSH
- Sanfilippo A/B/C/D, primarily neurological decline without somatic features in
childhood/adolescence.
MPS IVA - GALNS
- Morquio A, skeletal dysplasia, short stature, coronary, valve abnormalities.
MPS VI - ARSB
- Maroteaux-Lamy syndrome, skeletal, ophthalmologic, valvular abnormalities.
Multisystem involvement severity depends upon residual enzyme activities from unique
genetic etiologies across MPS subtypes.
Genetics of MPS
All are autosomal recessive except X-linked MPS II:
- Over 100 pathogenic variants degrade single enzyme activities through truncations,
missense changes impacting stability/catalytic function.
- Variable expressivity from allelic variants, somatic mosaicism impacting severity within
subtypes and between patients.
- Carrier testing assesses risks to relatives, prenatal/preimplantation diagnosis utilized by
carriers for progeny wellbeing.
Establishing causative variants confirms molecular diagnosis facilitating natural history
insights and guiding therapeutic intervention rationale.
Diagnosis
Suspicion stems from characteristic clinical/radiographic features:
- Dysmorphic facies, organomegaly, orthopedic/ocular abnormalities on examination.
- Elevated urinary GAGs by sulfated glycosaminoglycan assay initially screens.
- Enzyme activity assays on leukocytes/fibroblasts confirm specific deficiencies.
- Molecular analysis establishes causative variants in genes encoding deficient enzymes.
Baseline assessment guides establishing molecular diagnosis, prognosis estimation and
intervention planning through multidisciplinary care teams.
Management Strategies
Addressing multisystem involvement holistically:
- Palliative symptom management optimizes outcomes for neurological/non-CNS variants
ineligible for transplantation/ERT.
- Surgical corrections address visual, airway, cardiovascular abnormalities.
- Physical/occupational therapy maintains joint range of motion/mobility.
- Hematopoietic stem cell transplantation halts progression when available.
- Enzyme replacement therapy stabilizes/reverses manifestations in approved subtypes.
- Investigational intrathecal ERT explores neurological variants’ high CSF barriers.
- Preimplantation genetic diagnosis enables unaffected offspring.
Continued advances leveraging pathophysiological understanding promise further therapies
alleviating burdens from these lysosomal disorders’ progressive multi-organ involvement.
Future Directions
Progressing management through precision development:
- Clarifying genotype-phenotype correlations guides intervention timing.
- Advancing newborn screening/early diagnosis before irreversible damage occurs.
- Developing intrathecal/intraventricular ERT delivery across neurological variants.
- Gene therapies approach beyond hematopoietic cell transplantation.
- Disease modeling illuminates modifier genes impacting heterogeneity.
- Biomarkers sensitively monitor disease course under various interventions.
- Designing adjunctive small molecules targeting storage/pathology mechanisms.
Overall, interdisciplinary efforts decoding dysregulated GAG degradation promise refining
management frameworks through rational therapeutic targeting mitigating impact for
individuals living with these progressive multisystem disorders.
Mucopolysaccharidoses (MPS) represent a group of 11 inherited lysosomal storage disorders
arising from deficiencies in enzymes degrading glycosaminoglycans (GAGs). Substrate
accumulation disrupts connective tissues, bones, joints, cartilage, corneas, and organs. Seven
major types (I-VII) exist based upon deficiencies in specific enzymes degrading GAGs.
While variable in severity, progressive multisystem involvement causes major impairments
requiring lifelong care. Newborn screening, hematopoietic stem cell transplantation (HSCT),
and emerging enzyme replacement therapies (ERTs) benefit selected MPS populations.
Further understanding of disease pathogenesis promises novel therapies alleviating
progressive multi-organ involvement characterizing these disorders.
GAG Metabolism and Physiological Roles
Glycosaminoglycans (GAGs) crucially regulate tissue structure, cell signaling, and
development:
- Heparan sulfate, dermatan sulfate, chondroitin sulfate, keratan sulfate compose GAG
chainosities.
- Lysosomal hydrolases degrade GAG disaccharides and monomers for recycling or
excretion.
- Cell surface/extracellular matrix accumulation impacts morphogenesis, inflammatory
responses, growth factor binding when catabolized GAGs accumulate.
Deficient catabolic enzyme activities cause progressive GAG storage clinically evident across
MPS subtypes. Understanding substrate processing deficits rationalizes therapeutic targeting
strategies.
Clinical Features by Enzyme Deficiency
Dependent upon lysosomal deficiency, manifestations involve:
MPS I - IDUA
- Hurler (+/-Hurler-Scheie/Scheie variants), severe organomegaly, facial dysmorphism,
coronary artery, valve disease.
MPS II - IDS
- Hunter syndrome, primarily skeletal abnormalities, myocardial/valvular disease risk.
MPS III - SGSH
- Sanfilippo A/B/C/D, primarily neurological decline without somatic features in
childhood/adolescence.
MPS IVA - GALNS
- Morquio A, skeletal dysplasia, short stature, coronary, valve abnormalities.
MPS VI - ARSB
- Maroteaux-Lamy syndrome, skeletal, ophthalmologic, valvular abnormalities.
Multisystem involvement severity depends upon residual enzyme activities from unique
genetic etiologies across MPS subtypes.
Genetics of MPS
All are autosomal recessive except X-linked MPS II:
- Over 100 pathogenic variants degrade single enzyme activities through truncations,
missense changes impacting stability/catalytic function.
- Variable expressivity from allelic variants, somatic mosaicism impacting severity within
subtypes and between patients.
- Carrier testing assesses risks to relatives, prenatal/preimplantation diagnosis utilized by
carriers for progeny wellbeing.
Establishing causative variants confirms molecular diagnosis facilitating natural history
insights and guiding therapeutic intervention rationale.
Diagnosis
Suspicion stems from characteristic clinical/radiographic features:
- Dysmorphic facies, organomegaly, orthopedic/ocular abnormalities on examination.
- Elevated urinary GAGs by sulfated glycosaminoglycan assay initially screens.
- Enzyme activity assays on leukocytes/fibroblasts confirm specific deficiencies.
- Molecular analysis establishes causative variants in genes encoding deficient enzymes.
Baseline assessment guides establishing molecular diagnosis, prognosis estimation and
intervention planning through multidisciplinary care teams.
Management Strategies
Addressing multisystem involvement holistically:
- Palliative symptom management optimizes outcomes for neurological/non-CNS variants
ineligible for transplantation/ERT.
- Surgical corrections address visual, airway, cardiovascular abnormalities.
- Physical/occupational therapy maintains joint range of motion/mobility.
- Hematopoietic stem cell transplantation halts progression when available.
- Enzyme replacement therapy stabilizes/reverses manifestations in approved subtypes.
- Investigational intrathecal ERT explores neurological variants’ high CSF barriers.
- Preimplantation genetic diagnosis enables unaffected offspring.
Continued advances leveraging pathophysiological understanding promise further therapies
alleviating burdens from these lysosomal disorders’ progressive multi-organ involvement.
Future Directions
Progressing management through precision development:
- Clarifying genotype-phenotype correlations guides intervention timing.
- Advancing newborn screening/early diagnosis before irreversible damage occurs.
- Developing intrathecal/intraventricular ERT delivery across neurological variants.
- Gene therapies approach beyond hematopoietic cell transplantation.
- Disease modeling illuminates modifier genes impacting heterogeneity.
- Biomarkers sensitively monitor disease course under various interventions.
- Designing adjunctive small molecules targeting storage/pathology mechanisms.
Overall, interdisciplinary efforts decoding dysregulated GAG degradation promise refining
management frameworks through rational therapeutic targeting mitigating impact for
individuals living with these progressive multisystem disorders.
Mucopolysaccharidoses (MPS) represent a group of 11 inherited lysosomal storage disorders
arising from deficiencies in enzymes degrading glycosaminoglycans (GAGs). Substrate
accumulation disrupts connective tissues, bones, joints, cartilage, corneas, and organs. Seven
major types (I-VII) exist based upon deficiencies in specific enzymes degrading GAGs.
While variable in severity, progressive multisystem involvement causes major impairments
requiring lifelong care. Newborn screening, hematopoietic stem cell transplantation (HSCT),
and emerging enzyme replacement therapies (ERTs) benefit selected MPS populations.
Further understanding of disease pathogenesis promises novel therapies alleviating
progressive multi-organ involvement characterizing these disorders.
GAG Metabolism and Physiological Roles
Glycosaminoglycans (GAGs) crucially regulate tissue structure, cell signaling, and
development:
- Heparan sulfate, dermatan sulfate, chondroitin sulfate, keratan sulfate compose GAG
chainosities.
- Lysosomal hydrolases degrade GAG disaccharides and monomers for recycling or
excretion.
- Cell surface/extracellular matrix accumulation impacts morphogenesis, inflammatory
responses, growth factor binding when catabolized GAGs accumulate.
Deficient catabolic enzyme activities cause progressive GAG storage clinically evident across
MPS subtypes. Understanding substrate processing deficits rationalizes therapeutic targeting
strategies.
Clinical Features by Enzyme Deficiency
Dependent upon lysosomal deficiency, manifestations involve:
MPS I - IDUA
- Hurler (+/-Hurler-Scheie/Scheie variants), severe organomegaly, facial dysmorphism,
coronary artery, valve disease.
MPS II - IDS
- Hunter syndrome, primarily skeletal abnormalities, myocardial/valvular disease risk.
MPS III - SGSH
- Sanfilippo A/B/C/D, primarily neurological decline without somatic features in
childhood/adolescence.
MPS IVA - GALNS
- Morquio A, skeletal dysplasia, short stature, coronary, valve abnormalities.
MPS VI - ARSB
- Maroteaux-Lamy syndrome, skeletal, ophthalmologic, valvular abnormalities.
Multisystem involvement severity depends upon residual enzyme activities from unique
genetic etiologies across MPS subtypes.
Genetics of MPS
All are autosomal recessive except X-linked MPS II:
- Over 100 pathogenic variants degrade single enzyme activities through truncations,
missense changes impacting stability/catalytic function.
- Variable expressivity from allelic variants, somatic mosaicism impacting severity within
subtypes and between patients.
- Carrier testing assesses risks to relatives, prenatal/preimplantation diagnosis utilized by
carriers for progeny wellbeing.
Establishing causative variants confirms molecular diagnosis facilitating natural history
insights and guiding therapeutic intervention rationale.
Diagnosis
Suspicion stems from characteristic clinical/radiographic features:
- Dysmorphic facies, organomegaly, orthopedic/ocular abnormalities on examination.
- Elevated urinary GAGs by sulfated glycosaminoglycan assay initially screens.
- Enzyme activity assays on leukocytes/fibroblasts confirm specific deficiencies.
- Molecular analysis establishes causative variants in genes encoding deficient enzymes.
Baseline assessment guides establishing molecular diagnosis, prognosis estimation and
intervention planning through multidisciplinary care teams.
Management Strategies
Addressing multisystem involvement holistically:
- Palliative symptom management optimizes outcomes for neurological/non-CNS variants
ineligible for transplantation/ERT.
- Surgical corrections address visual, airway, cardiovascular abnormalities.
- Physical/occupational therapy maintains joint range of motion/mobility.
- Hematopoietic stem cell transplantation halts progression when available.
- Enzyme replacement therapy stabilizes/reverses manifestations in approved subtypes.
- Investigational intrathecal ERT explores neurological variants’ high CSF barriers.
- Preimplantation genetic diagnosis enables unaffected offspring.
Continued advances leveraging pathophysiological understanding promise further therapies
alleviating burdens from these lysosomal disorders’ progressive multi-organ involvement.
Future Directions
Progressing management through precision development:
- Clarifying genotype-phenotype correlations guides intervention timing.
- Advancing newborn screening/early diagnosis before irreversible damage occurs.
- Developing intrathecal/intraventricular ERT delivery across neurological variants.
- Gene therapies approach beyond hematopoietic cell transplantation.
- Disease modeling illuminates modifier genes impacting heterogeneity.
- Biomarkers sensitively monitor disease course under various interventions.
- Designing adjunctive small molecules targeting storage/pathology mechanisms.
Overall, interdisciplinary efforts decoding dysregulated GAG degradation promise refining
management frameworks through rational therapeutic targeting mitigating impact for
individuals living with these progressive multisystem disorders.
